Bioinorganic medicinal chemistry:
Gespeichert in:
| Weitere Verfasser: | |
|---|---|
| Format: | Buch |
| Sprache: | English |
| Veröffentlicht: |
Weinheim
Wiley-VCH
2011
|
| Schlagworte: | |
| Online-Zugang: | Inhaltstext Inhaltsverzeichnis |
| Beschreibung: | XVIII, 422 S. Ill., graph. Darst. |
| ISBN: | 9783527326310 |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV036854886 | ||
| 003 | DE-604 | ||
| 005 | 20111019 | ||
| 007 | t | ||
| 008 | 101207s2011 gw ad|| |||| 00||| eng d | ||
| 015 | |a 10,N32 |2 dnb | ||
| 016 | 7 | |a 1005391343 |2 DE-101 | |
| 020 | |a 9783527326310 |c GB. : EUR 139.00 (freier Pr.) |9 978-3-527-32631-0 | ||
| 035 | |a (OCoLC)706038576 | ||
| 035 | |a (DE-599)DNB1005391343 | ||
| 040 | |a DE-604 |b ger |e rakddb | ||
| 041 | 0 | |a eng | |
| 044 | |a gw |c XA-DE-BW | ||
| 049 | |a DE-20 |a DE-11 |a DE-29T | ||
| 082 | 0 | |a 615.2 |2 22/ger | |
| 084 | |a VH 9750 |0 (DE-625)147385:253 |2 rvk | ||
| 084 | |a VS 5000 |0 (DE-625)147681: |2 rvk | ||
| 084 | |a VS 5350 |0 (DE-625)147687:253 |2 rvk | ||
| 084 | |a 540 |2 sdnb | ||
| 084 | |a 610 |2 sdnb | ||
| 245 | 1 | 0 | |a Bioinorganic medicinal chemistry |c ed by Enzo Alessio |
| 264 | 1 | |a Weinheim |b Wiley-VCH |c 2011 | |
| 300 | |a XVIII, 422 S. |b Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 650 | 0 | 7 | |a Pharmazeutische Chemie |0 (DE-588)4132158-3 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Anorganische Verbindungen |0 (DE-588)4002147-6 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Pharmazeutische Chemie |0 (DE-588)4132158-3 |D s |
| 689 | 0 | 1 | |a Anorganische Verbindungen |0 (DE-588)4002147-6 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Alessio, Enzo |d 1958- |0 (DE-588)111755425 |4 edt | |
| 856 | 4 | 2 | |m X:MVB |q text/html |u http://deposit.dnb.de/cgi-bin/dokserv?id=3520444&prov=M&dok_var=1&dok_ext=htm |3 Inhaltstext |
| 856 | 4 | 2 | |m DNB Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=020770778&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-020770778 | |
Datensatz im Suchindex
| _version_ | 1805095075714170880 |
|---|---|
| adam_text |
IMAGE 1
CONTENTS
LIST OFCONTRIBUTORS XV
1 MEDICINAL INORGANIC CHEMISTRY: STATE OF THE ART, NEW TRENDS, AND A
VISION OF THE FUTURE 1 NICOLAJ. FARRER AND PETERJ. SADLER 1.1
INTRODUCTION 1
1.1.1 METALS IN THE BODY. ESSENTIAL ELEMENTS AND DISEASES OF METABOLISM
6 1.1.2 METALS AS THERAPEUTIC AGENTS 6 1.2 ANTIMICROBIAL AGENTS 8
1.3 ANTIVIRAL AGENTS 25
1.4 SYSTEMIC AND METABOLIE DISEASES INCLUDING INFLAMMATION 28 1.4.1
DIABETES AND OBESITY 28 1.4.2 METAL HOMEOSTASIS AND RELATED DISEASES 19
1.5 METAL CHELATING AGENTS 29 1.6 ANTIARTHRITIC DRUGS AND INFLAMMATION
21 1.7 BIPOLAR DISORDER 22
1.8 ANTICANCER AGENTS 22
1.8.1 PT" CYTOTOXIC AGENTS 23 1.8.2 PT IV PRODRUGS 24
1.8.3 PHOTOACTIVATABLE PT IV COMPLEXES 25 1.8.4 RUTHENIUM 25
1.8.4.1 INTERACTION WITH PLASMA PROTEINS 25 1.8.4.2 RUTHENIUM ARENES 26
1.8.5 OSMIUM 29
1.8.6 TITANIUM 29
1.8.7 GOLD 32
1.8.8 TIN 32
1.8.9 GALLIUM 33
BIOINORGANIC MEDICINAL CHEMISTRY. EDITED BY ENZO ALESSIO COPYRIGHT SS
2011 WILEY-VCH VERLAG GMBH & CO. KGAA, WEINHEIM ISBN: 978-3-527-32631-0
BIBLIOGRAFISCHE INFORMATIONEN HTTP://D-NB.INFO/1005391343
DIGITALISIERT DURCH
IMAGE 2
VI I CONTENTS
1.8.10 ARSENIC 33
1.8.11 COPPER 34 1.8.12 ZINC 34
1.8.13 BISMUTH 34 1.8.14 MOLYBDENUM 35 1.8.15 PHOTOSENSITIZERS:
PORPHYRINS 35 1.9 SMALL MOLECULE DELIVERY AND CONTROL 35 1.9.1 NITRIC
OXIDE (NO) 35 1.9.2 CARBON MONOXIDE (CO) 36 1.10 DIAGNOSTIC AGENTS 36
1.11 VETERINARY MEDICINAL INORGANIC CHEMISTRY 37 1.12 CONCLUSIONS AND
VISION 37
2 TARGETING STRATEGIES FOR METAL-BASED THERAPEUTICS 49 JULIA F. NORMAN
AND TREVOR W. HAMBLEY 2.1 INTRODUCTION 49
2.2 PHYSIOLOGICAL TARGETING 49 2.2.1 ANTITUMOR DRUGS TARGETING TUMOR
HYPOXIA 50 2.2.2 ANTITUMOR DRUGS TARGETING VASCULAR STRUCTURE 54 2.2.3
ANTITUMOR DRUGS TARGETING TUMOR PH 54 2.2.4 LIGHT ACTIVATED PRODRUGS 55
2.3 MOLECULAR TARGETING 57
2.3.1 PROTEIN AND PEPTIDE TARGETING 57 2.3.1.1 PROTEIN RECEPTOR BINDING
57 2.3.2 PEPTIDE TETHERING 63 2.3.2.1 DIRECTING EFFECTS 64 2.3.3
SELECTIVE ACTIVATION 65 2.3.4 DNA TARGETING 66 2.3.4.1 DUPLEX DNA
SEQUENCE SELECTIVITY 66 2.3.4.2 TELOMERIC TARGETING 68 2.4 IMMUNOLOGICAL
TARGETING 69 2.4.1 ANTIGEN TARGETING 70
2.4.2 ANTIBODY TETHERING 72 2.5 CONDUDING REMARKS 73
3 CURRENT STATUS AND MECHANISM OF ACTION OF PLATINUM-BASED ANTICANCER
DRUGS 79 SHANTA DHAR AND STEPHEN J. LIPPARD 3.1 INTRODUCTION 79
3.1.1 PLATINUM CHEMOTHERAPY AND CANCER 79 3.1.2 PALETTE OF CURRENT
PLATINUM CHEMOTHERAPEUTIC DRUGS 79 3.1.3 EARLY HISTORY OF CISPLATIN AND
APPROVED PLATINUM DRUGS FOR THE CLINIC 82
3.2 MECHANISM OF ACTION OF CISPLATIN 82 3.2.1 CISPLATIN ACCUMULATION 82
3.2.2 CISPLATIN ACTIVATION 82
IMAGE 3
CONTENTS | VII
3.2.2.1 BINDING TO DNA TARGETS 83
3.2.2.2 BINDING TO NON-DNA TARGETS 84 3.2.3 CELLULAR PROCESSING OF
PLATINUM-DNA ADDUCTS 84 3.2.3.1 CYTOTOXICITY ASSOCIATED WITH HIGH
MOBILITY GROUP (HMG) PROTEINS 85 3.2.3.2 CYTOTOXICITY ASSOCIATED WITH
NON-HMG PROTEINS 86
3.3 LIMITATIONS OF CURRENT PLATINUM-BASED COMPOUNDS: NEW STRATEGIES 87
3.4 NOVEL CONCEPTS IN THE DEVELOPMENT OF PLATINUM ANTITUMOR DRUGS 87
3.4.1 FUNCTIONALIZED SINGLE-WALLED CARBON NANOTUBES (SWNTS)
AS VEHIDES FOR DELIVERY OF PT(IV)-PRODRUGS 88 3.4.2 TARGETED
NANOPARTIDES FOR DELIVERY OF CISPLATIN FOR PROSTATE CANCER 89 3.4.3 GOLD
NANOPARTIDES AS DELIVERY VEHIDES FOR PLATINUM
COMPOUNDS 90
3.4.4 DELIVERY OF PT(IV) COMPOUNDS TARGETING CANCER CELL METABOLISM 92
3.5 CONDUDING REMARKS 93
4 NEW TRENDS AND FUTURE DEVELOPMENTS OF PLATINUM-BASED ANTITUMOR DRUGS
97 XIAOYONG WANG AND ZIJIAN CUO 4.1 INTRODUCTION 97
4.2 MECHANISMS OF ACTION AND RESISTANCE 99 4.2.1 MECHANISM OF ACTION 99
4.2.2 MECHANISM OF RESISTANCE 200 4.2.2.1 DECREASED DRUG ACCUMULATION
200
4.2.2.2 INCREASED DETOXIFICATION 202 4.2.2.3 ENHANCED REPAIR AND
INCREASED TOLERANCE TO DNA DAMAGE 202 4.2.2.4 REDUCED APOPTOTIC RESPONSE
AND ACTIVATION OF SURVIVAL PATHWAYS 202
4.3 MONOFUNCTIONAL PLATINUM(II) COMPLEXES 203 4.4 TRANS-PLATINUM(II)
COMPLEXES 207 4.5 MULTINUDEAR PLATINUM(II) COMPLEXES 224 4.6
PLATINUM(IV) COMPLEXES 224 4.7 DELIVERY OF PLATINUM DRUGS 230 4.8
CONCLUDING REMARKS AND FUTURE PERSPECTIVES 239
5 RUTHENIUM AND OTHER NON-PLATINUM ANTICANCER COMPOUNDS 252 LOANNIS
BRATSOS, TERESA CIANFERRARA, ENZO ALESSIO, CHRISTIAN G. HARTINGER,
MICHAEL A. JAKUPEC, AND BERNHARD K. KEPPLER
5.1 INTRODUCTION 252
5.2 RUTHENIUM ANTICANCER COMPOUNDS 252
IMAGE 4
VIII CONTENTS
5.2.1 CHEMICAL FEATURES OF RUTHENIUM COMPOUNDS 252
5.2.2 TRANS-[TETRACHLORIDOBIS(LH-INDAZOLE)RUTHENATE(III)] COMPLEXES AND
THEIR DEVELOPMENT 153 5.2.3 RUTHENIUM-DMSO COMPOUNDS: THE DEVELOPMENT OF
NAMI-A 156 5.2.3.1 CHEMICAL FEATURES OF NAMI-A 257 5.2.3.2 NAMI-A-TYPE
COMPLEXES 258 5.2.3.3 MECHANISM OF ACTION OF NAMI-A 259 5.2.4
HALF-SANDWICH RU-ORGANOMETALLICS 260 5.2.4.1 PIANO-STOOL RU-ARENE
COMPOUNDS 260
5.2.4.2 RAPTA COMPOUNDS 262 5.2.4.3 OTHER HALF-SANDWICH RU COMPOUNDS 263
5.3 FROM GALLIUM NITRATE TO ORAL GALLIUM COMPLEXES 264 5.4 TITANIUM
ANTICANCER COMPOUNDS 265 5.4.1 BUDOTITANE: THE FIRST TRANSITION METAL
COMPLEX IN CLINICAL
TRIALS IN THE POST-CISPLATIN ERA 165 5.4.2 TITANOCENE DICHLORIDE AND
RELATED COMPOUNDS 266 5.5 FERROCENE-DERIVED ANTICANCER AGENTS 266 5.6
THE MAIN GROUP ORGANOMETALLICS SPIROGERMANIUM
AND GERMANIUM-132 267 5.7 ARSENIC IN CANCER CHEMOTHERAPY 168 5.8
OVERCOMING THE RESISTANCE OF TUMORS TO ANTICANCER AGENTS BY RARE EARTH
ELEMENT COMPOUNDS 269 5.9 CONDUSIONS 270
6 THE CHALLENGE OF ESTABLISHING RELIABLE SCREENING TESTS FOR SELECTING
ANTICANCER METAL COMPOUNDS 175 ANGELA BOCCARELLI, ALESSANDRA PANNUNZIO,
AND MAURO COLUCCIA 6.1 INTRODUCTION 175
6.2 TUMOR CELL GROWTH INHIBITION AND CELL DEATH SCREENING ASSAYS 177 6.3
METAL-BASED ANTICANCER COMPOUNDS AND GENE EXPRESSION MICROARRAY
TECHNOLOGIES 282 6.3.1 BASAI TRANSCRIPTION PROFILING AND
SENSITIVITY/RESISTANCE
TO METAL-BASED ANTICANCER DRUGS 183 6.3.2 PROFILING GENE EXPRESSION
ALTERATIONS IN RESPONSE TO TREATMENT WITH METAL-BASED ANTICANCER DRUGS
285 6.4 METAL-BASED ANTICANCER COMPOUNDS AND THE PROTEOMIC
APPROACH 287
6.5 CONCLUDING REMARKS 290
6.5.1 CYTOTOXIC METAL-BASED ANTICANCER AGENTS 290 6.5.2 NON-CYTOTOXIC
METAL-BASED ANTICANCER AGENTS 290 6.5.3 TUMOR-TARGETED METAL-BASED
ANTICANCER AGENTS 292 6.5.4 TOWARDS A GLOBAL MECHANISTIC-BASED SCREENING
APPROACH 292
IMAGE 5
CONTENTS IX
7 GOLD-BASED THERAPEUTIC AGENTS: A NEW PERSPECTIVE 297
SUSAN J. BERNERS-PRICE
7.1 INTRODUCTION 197
7.1.1 AN HISTORICAL PERSPECTIVE 297 7.1.2 CURRENT INTEREST IN GOLD-BASED
DRUGS 199 7.2 BIOLOGICAL CHEMISTRY OF GOLD 200 7.2.1 GOLD(I) OXIDATION
STATE 200 7.2.2 GOLD(III) OXIDATION STATE 202 73 GOLD ANTIARTHRITIC
DRUGS 202 7.3.1 STRUCTURAL CHEMISTRY AND BIOTRANSFORMATION REACTIONS 202
7.3.2 MODE OF ACTION 204 7.4 GOLD COMPLEXES AS ANTICANCER AGENTS 205
7.4.1 GOLD(I) COMPOUNDS 205 7.4.1.1 AURANOFIN AND RELATED COMPOUNDS 205
7.4.1.2 TETRAHEDRAL GOLD(I) DIPHOSPHINES AND RELATED COMPOUNDS 206
7.4.1.3 GOLD(I) N-HETEROCYCLIC CARBENE COMPOUNDS 209 7.4.2 GOLD (III)
COMPOUNDS 210 7A3 MODE OF ACTION OF GOLD-BASED ANTICANCER DRUGS 222 7.5
GOLD COMPLEXES AS ANTIPARASITIC AGENTS 224 7.6 CONCLUDING REMARKS 225
8 M RI CONTRAST AGENTS: STATE OF THE ART AND NEW TRENDS 223 DANIELA
DELLI CASTELLI, ELIANA CIANOLIO, AND SILVIO AIME 8.1 INTRODUCTION 223
8.2 TJ AGENTS 224
8.2.1 THEORY OF PARAMAGNETIC RELAXATION 224 8.2.2 CLINICALLY APPROVED TJ
AGENTS 227 8.2.2.1 PARAMAGNETIC GD(III)-BASED COMPLEXES 227 8.2.2.2
MN(II)-BASED COMPLEXES 229 8.2.3 PRECLINICAL LEVEL 230 8.2.3.1 ECF
AGENTS 230 8.2.3.2 BLOOD POOL AGENTS 231 8.2.3.3 RESPONSIVE TJ AGENTS
232
8.3 T 2 -SUSCEPTIBILITY AGENTS 234 8.3.1 IRON OXIDE PARTIDES 235 8.3.2
PARAMAGNETIC LIPOSOMES 235 8.4 CEST AGENTS 236
8.4.1 THEORETICAL BACKGROUND 237 8.4.1.1 THE SENSITIVITY ISSUE 239 8.4.2
PARAMAGNETIC CEST AGENTS: PARACEST 242 8.4.2.1 RESPONSIVE PARACEST
AGENTS 244 8.4.2.2 CELL LABELING 248 8.5 CONCLUDING REMARKS 249
IMAGE 6
CONTENTS
9 METAL-BASED RADIOPHARMACEUTICALS 253 ROGER ALBERTO 9.1 INTRODUCTION
253
9.1.1 SELECTION OF THE RADIONUCLIDE 254 9.1.2 PRODUCTION OF
RADIONUCLIDES 255 9.1.3 CONCEPTS AND CHEMISTRY OF LABELING 258 9.1.4
DIFFERENT GENERATIONS OF METAL-BASED
RADIOPHARMACEUTICALS 260 9.2 SELECTED EXAMPLES: THERAPEUTIC
RADIOPHARMACEUTICALS 262 9.2.1 THE "3 + FAMILY": YTTRIUM AND SOME
LANTHANIDES 262 9.2.2 RHENIUM 265
9.2.3 OC-EMITTERS: BISMUTH AND ACTINIUM 267 9.3 DIAGNOSTIC METAL-BASED
RADIOPHARMACEUTICALS 269 9.3.1 THE "3 + FAMILY CONTINUED": INDIUM AND
GALLIUM 269 9.3.2 TECHNETIUM 272
9.3.3 TARGETED RADIOPHARMACEUTICALS: TECHNETIUM-LABELED CARBOHYDRATES
274 9.3.4 TEDINETIUM-ESSENTIAL RADIOPHARMACEUTICALS FOR HEART IMAGING
276 9.4 PERSPECTIVES AND CONDUSION 278
10 BORON AND GADOLINIUM IN THE NEUTRON CAPTURE THERAPY OF CANCER 283
ELLEN L CROSSLEY, H. Y. VINCENT CHING, JOSEPH A. LOPPOLO, AND LOUIS M.
RENDINA
10.1 INTRODUCTION 283
10.2 BORON NEUTRON CAPTURE THERAPY 284 10.2.1 KEY CRITERIA FOR BNCT
AGENTS 285 10.2.2 CLINICAL BNCT AGENTS 286 10.3 ROLE OF MEDICINAL
INORGANIC CHEMISTRY IN BNCT 287 10.3.1 PLARINUM-BORON AGENTS 288
10.3.2 BORONATED PORPHYRINS 289 10.3.3 BORONATED PHOSPHONIUM SALTS 290
10.3.4 RADIOLABELING OF BORONATED AGENTS FOR IN VIVO IMAGING 291 10.3.5
RADIOFLUORINATION OF BPA 292
10.3.6 CARBORANE RADIOHALOGENATION 292 10.3.7 RADIOMETALLACARBORANES 293
10.4 GADOLINIUM NEUTRON CAPTURE THERAPY 294 10.4.1 ARCHETYPAL GD NCT
AGENTS 295 10.4.2 HYBRID BORON-GADOLINIUM AGENTS 296 10.5 CONCLUSIONS
AND FUTURE OUTLOOK 297
IMAGE 7
CONTENTS XI
11 ESSENTIAL METAL RELATED METABOLIE DISORDERS 307
YASMIN MAWANI AND CHRIS ORVIG 11.1 INTRODUCTION: WHAT IS ESSENTIALITY?
307 11.2 IRON METABOLIE DISEASES: ACQUIRED AND GENETIC 307 11.2.1 IRON
HOMEOSTASIS 307 11.2.2 DISEASES OF PRIMARY IRON OVERLOAD:
HEMOCHROMATOSIS 309 11.2.2.1 TYPE 1 HEREDITARY HEMOCHROMATOSIS 309
11.2.2.2 TYPE 2 HEREDITARY HEMOCHROMATOSIS: JUVENILE
HEMOCHROMATOSIS 309 11.2.2.3 TYPE 3 HEREDITARY HEMOCHROMATOSIS 312
11.2.2.4 TYPE 4 HEREDITARY HEMOCHROMATOSIS: AFRICAN IRON OVERLOAD 312
11.2.2.5 NEONATAL HEMOCHROMATOSIS 312 11.2.3 DISEASES OF IRON OVERLOAD:
ACCUMULATION OF IRON IN THE BRAIN 312 11.2.3.1 ACERULOPLASMINEMIA 312
11.2.3.2 HALLERVORDEN-SPATZ SYNDROME (HSS) 322 11.2.3.3 FRIEDREICH'S
ATAXIA 312 11.2.4 ACQUIRED IRON OVERLOAD DISORDERS 313 11.2.5 TREATMENT
OF IRON OVERLOAD DISORDERS: CHELATION THERAPY 313 11.2.6 IRON DEFICIENCY
314 11.3 COPPER METABOLIE DISEASES 325 11.3.1 COPPER HOMEOSTASIS 325
11.3.2 COPPER DEFICIENCY: MENKES DISEASE 317 11.3.3 COPPER OVERLOAD:
WILSON'S DISEASE 318 11.3.4 TREATMENT OF WILSON'S DISEASE: CHELATION
THERAPY 318 11.4 ZINC METABOLIE DISEASES 319 11.4.1 ZINC HOMEOSTASIS 329
11.4.2 ZINC OVERLOAD: ZINC TOXICITY 321
11.4.3 TREATMENT OF ZINC TOXICITY: CHELATION THERAPY 321 11.4.4 ACQUIRED
ZINC DEFICIENCY 322 11.4.5 GENETIC ZINC DEFICIENCY: ACRODERMATITIS
ENTEROPHATHICA 322 11.5 DISEASES RELATED TO IMBALANCES IN ELECTROLYTIC
METABOLISM:
P, THE ALKALI METALS, AND THE ALKALINE EARTHS 323 11.5.1 SODIUM 324
11.5.1.1 HYPONATREMIA 326 11.5.1.2 HYPERNATREMIA 327 11.5.2 MAGNESIUM
328 11.5.2.1 HYPOMAGNESEMIA 328 11.5.2.2 HYPERMAGNESEMIA 329 11.5.3
POTASSIUM 330 11.5.3.1 HYPOKALEMIA 330 11.5.3.2 HYPERKALEMIA 332
11.5.4 PHOSPHORUS 332 11.5.4.1 HYPOPHOSPHATEMIA 333
IMAGE 8
XII CONTENTS
11.5.4.2 HYPOPHOSPHATASIA 334
11.5.4.3 HYPERPHOSPHATEMIA 335 11.5.5 CALCIUM 336 11.5.5.1 VITAMIN D 336
11.5.5.2 PARATHYROID HORMONE 337 11.5.5.3 HYPOCALCEMIA 337 11.5.5.4
HYPERCALCEMIA 337 11.5.5.5 DISEASES RELATED TO THE PARATHYROID HORMONE
338 11.5.5.6 HYPERPARATHYROIDISM (HPT) 339
11.5.5.7 OSTEOMALACIA 340 11.5.5.8 MILK-ALKALI SYNDROME 340 11.5.5.9
CALCIFYING DISORDERS 340
11.6 METABOLISM OF OTHER TRACE ELEMENTS 342 11.6.1 QUESTIONABLE
ESSENTIALITY OF NICKEL, MOLYBDENUM, AND VANADIUM 341 11.6.1.1 NICKEL 342
11.6.1.2 MOLYBDENUM 342 11.6.1.3 VANADIUM 342 11.6.2 CHROMIUM 343 11.6.3
COBALT AND VITAMIN B 12 344 11.6.4 MANGANESE 344 11.6.5 SELENIUM 345
11.7 CONCLUSIONS 346
12 METAL COMPOUNDS AS ENZYME INHIBITORS 351 CILLES CASSER AND NILS
METZLER-NOLTE 12.1 INTRODUCTION 351
12.2 KINASE INHIBITORS 352
12.3 PROTEASOME INHIBITORS 354 12.4 CARBONIC ANHYDRASE INHIBITORS (CAIS)
355 12.5 CYCLOOXYGENASE INHIBITORS 358 12.6 ACETYLCHOLINESTERASE
INHIBITORS 362
12.7 PROTEIN PHOSPHATASE INHIBITORS 362 12.8 TRYPSIN AND THROMBIN
INHIBITORS 363 12.9 CYSTEINE PROTEASE INHIBITORS AND GLUTATHIONE
TRANSFERASE INHIBITORS 365
12.10 HIV-1 REVERSE TRANSCRIPTASE AND PROTEASE INHIBITORS 368 12.11
TELOMERASE INHIBITORS 369 12.12 ZINC FINGER PROTEIN INHIBITORS 372 12.13
CXCR4 INHIBITORS 372 12.14 XANTHINE OXIDASE INHIBITORS 374 12.15
MISCELLANEOUS PROTEIN INHIBITORS AND CONCLUSIONS 374
IMAGE 9
CONTENTS XIII
13 BIOMEDICAL APPLICATIONS OF METAL-CONTAINING
LUMINOPHORES 383 ALBERT RUGGI, DAVID N. REINHOUDT, AND ALDRIK H. VELDERS
13.1 INTRODUCTION: LUMINESCENCE IN DIAGNOSTICS AND IMAGING 383 13.2
TRANSITION-METAL CONTAINING LUMINESCENT AGENTS 386 13.2.1 PHOTOPHYSICAL
PROPERTIES OF TRANSITION METAL COMPLEXES 386 13.2.2 RUTHENIUM(II)
COMPLEXES 388
13.2.2.1 DNA BINDING 388 13.2.2.2 PROTEIN BINDING 390 13.2.2.3 CELL
STAINING 390 13.2.3 IRIDIUM(III) COMPLEXES 391
13.2.4 RHENIUM(I) COMPLEXES 392 13.2.5 PLATINUM(II) COMPLEXES 393 13.2.6
OTHER METAL COMPLEXES 393 13.3 LANTHANIDE-BASED LUMINOPHORES 394
13.3.1 CHEMICAL AND PHOTOPHYSICAL PROPERTIES OF LANTHANIDE COMPLEXES 394
13.3.2 EUROPIUM(III) AND TERBIUM(III) COMPLEXES 396 13.3.2.1
IMMUNOASSAYS 396 13.3.2.2 NUDEIC ACID PROBES 398 13.3.2.3 MOLECULAR
IMAGING 398 13.3.3 NEODYMIUM(III) AND YTTERBIUM(III) COMPLEXES 399 13.4
NANOPARTIDE-BASED LUMINOPHORES 399 13.4.1 CHEMICAL AND PHOTOPHYSICAL
PROPERTIES OF LUMINESCENT
NANOPARTIDES 399
13.4.2 SEMICONDUCTOR QUANTUM DOTS 400 13.4.3 METAL-DOPED NANOPARTIDES
402 13.5 CONCLUSIONS AND PERSPECTIVES 402
INDEX 407 |
| any_adam_object | 1 |
| author2 | Alessio, Enzo 1958- |
| author2_role | edt |
| author2_variant | e a ea |
| author_GND | (DE-588)111755425 |
| author_facet | Alessio, Enzo 1958- |
| building | Verbundindex |
| bvnumber | BV036854886 |
| classification_rvk | VH 9750 VS 5000 VS 5350 |
| ctrlnum | (OCoLC)706038576 (DE-599)DNB1005391343 |
| dewey-full | 615.2 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615.2 |
| dewey-search | 615.2 |
| dewey-sort | 3615.2 |
| dewey-tens | 610 - Medicine and health |
| discipline | Chemie / Pharmazie Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>00000nam a2200000 c 4500</leader><controlfield tag="001">BV036854886</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20111019</controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">101207s2011 gw ad|| |||| 00||| eng d</controlfield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">10,N32</subfield><subfield code="2">dnb</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">1005391343</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783527326310</subfield><subfield code="c">GB. : EUR 139.00 (freier Pr.)</subfield><subfield code="9">978-3-527-32631-0</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)706038576</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DNB1005391343</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakddb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">gw</subfield><subfield code="c">XA-DE-BW</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-20</subfield><subfield code="a">DE-11</subfield><subfield code="a">DE-29T</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615.2</subfield><subfield code="2">22/ger</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">VH 9750</subfield><subfield code="0">(DE-625)147385:253</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">VS 5000</subfield><subfield code="0">(DE-625)147681:</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">VS 5350</subfield><subfield code="0">(DE-625)147687:253</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">540</subfield><subfield code="2">sdnb</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">610</subfield><subfield code="2">sdnb</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Bioinorganic medicinal chemistry</subfield><subfield code="c">ed by Enzo Alessio</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Weinheim</subfield><subfield code="b">Wiley-VCH</subfield><subfield code="c">2011</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XVIII, 422 S.</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Pharmazeutische Chemie</subfield><subfield code="0">(DE-588)4132158-3</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Anorganische Verbindungen</subfield><subfield code="0">(DE-588)4002147-6</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Pharmazeutische Chemie</subfield><subfield code="0">(DE-588)4132158-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Anorganische Verbindungen</subfield><subfield code="0">(DE-588)4002147-6</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Alessio, Enzo</subfield><subfield code="d">1958-</subfield><subfield code="0">(DE-588)111755425</subfield><subfield code="4">edt</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">X:MVB</subfield><subfield code="q">text/html</subfield><subfield code="u">http://deposit.dnb.de/cgi-bin/dokserv?id=3520444&prov=M&dok_var=1&dok_ext=htm</subfield><subfield code="3">Inhaltstext</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">DNB Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=020770778&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-020770778</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV036854886 |
| illustrated | Illustrated |
| indexdate | 2024-07-20T10:53:31Z |
| institution | BVB |
| isbn | 9783527326310 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-020770778 |
| oclc_num | 706038576 |
| open_access_boolean | |
| owner | DE-20 DE-11 DE-29T |
| owner_facet | DE-20 DE-11 DE-29T |
| physical | XVIII, 422 S. Ill., graph. Darst. |
| publishDate | 2011 |
| publishDateSearch | 2011 |
| publishDateSort | 2011 |
| publisher | Wiley-VCH |
| record_format | marc |
| spelling | Bioinorganic medicinal chemistry ed by Enzo Alessio Weinheim Wiley-VCH 2011 XVIII, 422 S. Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier Pharmazeutische Chemie (DE-588)4132158-3 gnd rswk-swf Anorganische Verbindungen (DE-588)4002147-6 gnd rswk-swf (DE-588)4143413-4 Aufsatzsammlung gnd-content Pharmazeutische Chemie (DE-588)4132158-3 s Anorganische Verbindungen (DE-588)4002147-6 s DE-604 Alessio, Enzo 1958- (DE-588)111755425 edt X:MVB text/html http://deposit.dnb.de/cgi-bin/dokserv?id=3520444&prov=M&dok_var=1&dok_ext=htm Inhaltstext DNB Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=020770778&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Bioinorganic medicinal chemistry Pharmazeutische Chemie (DE-588)4132158-3 gnd Anorganische Verbindungen (DE-588)4002147-6 gnd |
| subject_GND | (DE-588)4132158-3 (DE-588)4002147-6 (DE-588)4143413-4 |
| title | Bioinorganic medicinal chemistry |
| title_auth | Bioinorganic medicinal chemistry |
| title_exact_search | Bioinorganic medicinal chemistry |
| title_full | Bioinorganic medicinal chemistry ed by Enzo Alessio |
| title_fullStr | Bioinorganic medicinal chemistry ed by Enzo Alessio |
| title_full_unstemmed | Bioinorganic medicinal chemistry ed by Enzo Alessio |
| title_short | Bioinorganic medicinal chemistry |
| title_sort | bioinorganic medicinal chemistry |
| topic | Pharmazeutische Chemie (DE-588)4132158-3 gnd Anorganische Verbindungen (DE-588)4002147-6 gnd |
| topic_facet | Pharmazeutische Chemie Anorganische Verbindungen Aufsatzsammlung |
| url | http://deposit.dnb.de/cgi-bin/dokserv?id=3520444&prov=M&dok_var=1&dok_ext=htm http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=020770778&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT alessioenzo bioinorganicmedicinalchemistry |